{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:27:22Z","timestamp":1793809642995,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ymthe.2026.08.022","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:11:25Z","timestamp":1786633885000},"page":"6346-6357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy"],"prefix":"10.1016","volume":"34","author":[{"given":"Xueyan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8438-8852","authenticated-orcid":false,"given":"Jianhua","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.08.022_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2026.08.022_bib2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA Nephropathy: An Interesting Autoimmune Kidney Disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ymthe.2026.08.022_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D\u2019Amico","year":"2004","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.36469\/jheor.2021.26129","article-title":"A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy","volume":"8","author":"Kwon","year":"2021","journal-title":"J. Health Econ. Outcom"},{"key":"10.1016\/j.ymthe.2026.08.022_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2026.08.022_bib6","first-page":"355","article-title":"Long-Term Follow-up of Iga Mesangial Nephropathy - Clinico-Histological Study in 374 Patients","volume":"7","author":"Damico","year":"1987","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The Pathophysiology of IgA Nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA Nephropathy: Core Curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ymthe.2026.08.022_bib9","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1","volume":"30","author":"Rizk","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib10","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ndt\/gfn441","article-title":"Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy","volume":"24","author":"Lai","year":"2008","journal-title":"Nephrol. Dial Transpl."},{"key":"10.1016\/j.ymthe.2026.08.022_bib12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.1987.72","article-title":"Complement Membrane Attack (Mac) in Idiopathic Iga-Glomerulonephritis","volume":"31","author":"Rauterberg","year":"1987","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2026.08.022_bib13","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current Understanding of the Role of Complement in IgA Nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.it.2017.03.003","article-title":"Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery","volume":"38","author":"Mastellos","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.022_bib16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymthe.2026.08.022_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.23876\/j.krcp.21.248","article-title":"Application of C5 inhibitors in glomerular diseases in 2021","volume":"41","author":"Werion","year":"2022","journal-title":"Kidney Res. Clin. Prac."},{"key":"10.1016\/j.ymthe.2026.08.022_bib18","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria","volume":"99","author":"Scheinberg","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib19","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2026.08.022_bib20","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","article-title":"Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria","volume":"101","author":"Wong","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib21","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/0929867033368493","article-title":"Gene silencing mediated by small interfering RNAs in mammalian cells","volume":"10","author":"Scherr","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ymthe.2026.08.022_bib23","first-page":"590","article-title":"RNAi as a gene therapy approach","volume":"31","author":"Wang","year":"2004","journal-title":"Prog. Biochem. Biophys."},{"key":"10.1016\/j.ymthe.2026.08.022_bib24","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0140-6736(03)14637-5","article-title":"Small RNA: can RNA interference be exploited for therapy?","volume":"362","author":"Wall","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.ymthe.2026.08.022_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10735-004-2192-8","article-title":"RNA interference: The molecular immune system","volume":"35","author":"Bagasra","year":"2004","journal-title":"Histochem. J."},{"key":"10.1016\/j.ymthe.2026.08.022_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve Performance of GaINAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.08.022_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.08.022_bib28","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2026.08.022_bib29","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1007\/s00467-023-05968-0","article-title":"A pediatric case of IgA nephropathy benefitting from targeted release formulation-budesonide","volume":"38","author":"Antonucci","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib30","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.34067\/KID.0000000583","article-title":"Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results","volume":"5","author":"Zhang","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.ymthe.2026.08.022_bib31","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.022_bib32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and Its Receptors: New Insights into Human Disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2026.08.022_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.08.022_bib34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-3476(84)80479-5","article-title":"A Simple Estimate of Glomerular-Filtration Rate in Full-Term Infants during the 1st Year of Life","volume":"104","author":"Schwartz","year":"1984","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.08.022_bib35","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1667\/RADE-23-00062.1","article-title":"A New Method for Estimating Glomerular Filtration Rate in Rhesus Macaques (Macaca mulatta)","volume":"200","author":"Tomasino","year":"2023","journal-title":"Radiat. Res."},{"key":"10.1016\/j.ymthe.2026.08.022_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3949\/ccjm.92a.24105","article-title":"IgA nephropathy: Update on pathogenesis and treatment","volume":"92","author":"Ramsawak","year":"2025","journal-title":"Clev Clin. J. Med."},{"key":"10.1016\/j.ymthe.2026.08.022_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The Nonclinical Disposition and Pharmacokinetic\/Pharmacodynamic Properties of N-Acetylgalactosamine-Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626007033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:01:12Z","timestamp":1793808072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626007033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1525001626007033"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.10.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}